These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 31597832)

  • 1. [The beneficial effects of iron supplementation other than improvement of anemia].
    Hamano T
    Rinsho Ketsueki; 2019; 60(9):1092-1099. PubMed ID: 31597832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Iron deficiency : a new target in treating chronic heart failure ?].
    Borgeaud M; Perrier A
    Rev Med Suisse; 2016 Oct; 12(535):1747-1751. PubMed ID: 28692214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single dose of intravenous ferric carboxymaltose infusion versus multiple fractionated doses of intravenous iron sucrose in the treatment of postoperative anaemia in colorectal cancer patients: study protocol for a randomised controlled trial.
    Laso-Morales MJ; Vives R; Vallejo-Tarrat A; Caló N; Valle-Beltran A; Pontes C
    Trials; 2019 Jan; 20(1):23. PubMed ID: 30616657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of ferric Carboxymaltose and iron sucrose complex for treatment of iron deficiency anemia in pregnancy- randomised controlled trial.
    Jose A; Mahey R; Sharma JB; Bhatla N; Saxena R; Kalaivani M; Kriplani A
    BMC Pregnancy Childbirth; 2019 Feb; 19(1):54. PubMed ID: 30717690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized Trial Comparing Proactive, High-Dose versus Reactive, Low-Dose Intravenous Iron Supplementation in Hemodialysis (PIVOTAL): Study Design and Baseline Data.
    Macdougall IC; White C; Anker SD; Bhandari S; Farrington K; Kalra PA; McMurray JJV; Murray H; Steenkamp R; Tomson CRV; Wheeler DC; Winearls CG; Ford I;
    Am J Nephrol; 2018; 48(4):260-268. PubMed ID: 30304714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Iron deficiency in heart failure.
    Dinatolo E; Dasseni N; Metra M; Lombardi C; von Haehling S
    J Cardiovasc Med (Hagerstown); 2018 Dec; 19(12):706-716. PubMed ID: 30222663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of efficacy and safety between intravenous ferric carboxymaltose and saccharated ferric oxide in Japanese patients with iron-deficiency anemia due to hypermenorrhea: a multi-center, randomized, open-label noninferiority study.
    Ikuta K; Hanashi H; Hirai K; Ota Y; Matsuyama Y; Shimura A; Terauchi M; Momoeda M
    Int J Hematol; 2019 Jan; 109(1):41-49. PubMed ID: 30039442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching iron sucrose to ferric carboxymaltose associates to better control of iron status in hemodialysis patients.
    Hofman JMG; Eisenga MF; Diepenbroek A; Nolte IM; van Dam B; Westerhuis R; Bakker SJL; Franssen CFM; Gaillard CAJM
    BMC Nephrol; 2018 Sep; 19(1):242. PubMed ID: 30236065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iron substitution in the treatment of chronic heart failure.
    Gstrein C; Meyer M; Anabitarte P
    Swiss Med Wkly; 2017; 147():w14453. PubMed ID: 28695549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Systematic Review, Meta-Analysis, and Indirect Comparison of Blindly Adjudicated Cardiovascular Event Incidence with Ferric Derisomaltose, Ferric Carboxymaltose, and Iron Sucrose.
    Pollock RF; Kalra PA; Kalra PR; Ahmed FZ
    Adv Ther; 2022 Oct; 39(10):4678-4691. PubMed ID: 35947351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study.
    Ponikowski P; Filippatos G; Colet JC; Willenheimer R; Dickstein K; Lüscher T; Gaudesius G; von Eisenhart Rothe B; Mori C; Greenlaw N; Ford I; Macdougall I; Anker SD;
    Eur J Heart Fail; 2015 Mar; 17(3):329-39. PubMed ID: 25683972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switching patients with non-dialysis chronic kidney disease from oral iron to intravenous ferric carboxymaltose: effects on erythropoiesis-stimulating agent requirements, costs, hemoglobin and iron status.
    Toblli JE; Di Gennaro F
    PLoS One; 2015; 10(4):e0125528. PubMed ID: 25928811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Anaemia and iron deficiency in clinical practice:from cardiology to gastroenterology and beyond].
    Češka R
    Vnitr Lek; 2014 Dec; 60(12):1033-9. PubMed ID: 25692829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ferric carboxymaltose in patients with heart failure and iron deficiency.
    Anker SD; Comin Colet J; Filippatos G; Willenheimer R; Dickstein K; Drexler H; Lüscher TF; Bart B; Banasiak W; Niegowska J; Kirwan BA; Mori C; von Eisenhart Rothe B; Pocock SJ; Poole-Wilson PA; Ponikowski P;
    N Engl J Med; 2009 Dec; 361(25):2436-48. PubMed ID: 19920054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative efficacy and safety of intravenous ferric carboxymaltose and iron sucrose for the treatment of preoperative anemia in patients with menorrhagia: An open-label, multicenter, randomized study.
    Lee S; Ryu KJ; Lee ES; Lee KH; Lee JJ; Kim T
    J Obstet Gynaecol Res; 2019 Apr; 45(4):858-864. PubMed ID: 30932300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial.
    Onken JE; Bregman DB; Harrington RA; Morris D; Buerkert J; Hamerski D; Iftikhar H; Mangoo-Karim R; Martin ER; Martinez CO; Newman GE; Qunibi WY; Ross DL; Singh B; Smith MT; Butcher A; Koch TA; Goodnough LT
    Nephrol Dial Transplant; 2014 Apr; 29(4):833-42. PubMed ID: 23963731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and safety of ferric carboxymaltose compared to iron sucrose in women with iron deficiency anemia: phase IV clinical trials.
    Naqash A; Ara R; Bader GN
    BMC Womens Health; 2018 Jan; 18(1):6. PubMed ID: 29304848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of ferric carboxymaltose in correcting iron-deficiency anemia: a review of randomized controlled trials across different indications.
    Bailie GR
    Arzneimittelforschung; 2010; 60(6a):386-98. PubMed ID: 20648930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Budget impact of intravenous ferric carboxymaltose in patients with chronic heart failure and iron deficiency in France.
    Bourguignon S; Faller M; Champs FO; Moutier H; Levesque K; Caranhac G; Cohen-Solal A
    ESC Heart Fail; 2019 Jun; 6(3):559-569. PubMed ID: 31021531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of intravenous ferric carboxymaltose on red cell distribution width: a subanalysis of the FAIR-HF study.
    Van Craenenbroeck EM; Conraads VM; Greenlaw N; Gaudesius G; Mori C; Ponikowski P; Anker SD
    Eur J Heart Fail; 2013 Jul; 15(7):756-62. PubMed ID: 23639779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.